Table 2.
Prescribed medications for COPD in the PMC and control group patients
| Prescribed medication | Baseline
|
12-month treatment
|
||
|---|---|---|---|---|
| PMC group, n (%) | Control group, n (%) | PMC group, n (%) | Control group, n (%) | |
| SABA | 55 (45.0) | 54 (44.2) | 51 (44.7) | 49 (43.3) |
| LABA/ICS | 58 (47.5) | 50 (40.9) | 68 (59.6) | 64 (56.6) |
| LABA | 14 (11.4) | 15 (12.3) | 17 (14.9) | 16 (14.2) |
| LAMA | 63 (51.6) | 62 (50.8) | 84 (73.6) | 81 (71.6) |
| Oral steroids | 7 (5.7) | 9 (7.4) | 8 (7.0) | 5 (4.4) |
| Anticholinergic agents | 32 (26.2) | 35 (28.6) | 37 (32.4) | 38 (33.6) |
| Xanthines | 22 (18.0) | 25 (20.4) | 24 (21.0) | 25 (19.4) |
| P-value | 0.74 | 0.63 | ||
Abbreviations: PMC, pharmacist-managed clinic; SABA, short-acting β2 agonist; LABA, long-acting β2 agonist; ICS, inhaled corticosteroid; LAMA, long-acting muscarinic antagonist.